BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Celgene (CELG): A Biotech Takeover Target?]]>http://www.bloggingstocks.com/2011/02/15/celgene-celg-a-biotech-takeover-target/http://www.bloggingstocks.com/2011/02/15/celgene-celg-a-biotech-takeover-target/http://www.bloggingstocks.com/2011/02/15/celgene-celg-a-biotech-takeover-target/#commentsFiled under: ,

Celgene logo"As tradition holds, Celgene (CELG) gave the first presentation at the recent 29th JP Morgan Healthcare Conference, where CEO Bog Hugin focused on Celgene's ongoing plans to become a world-wide company and expansion into global markets," reports John McCamant.

The biotech specialist and editor of The Medical Technology Stock Letter explains, "They expect 2011 to be the first year where the company earns a majority of sales outside the U.S. The company is currently conducting 25 Phase III trials on its various drugs.

"Celgene also announced 4th quarter 2010 earnings last week, and revenue was down 16%, mostly based on costs incurred due to the Abraxis acquisition.

Continue reading Celgene (CELG): A Biotech Takeover Target?

Celgene (CELG): A Biotech Takeover Target? originally appeared on BloggingStocks on Tue, 15 Feb 2011 13:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech stocksbiotechnologycancer treatment stockscelgenefeaturedjohn mccamantmedical technology stock letterRevlimidsteven halperntakeover stocksthestockadvisors.comTue, 15 Feb 2011 13:00:00 EST<![CDATA[Celgene Remains in an Uptrend]]>http://www.bloggingstocks.com/2009/12/21/celgene-remains-in-an-uptrend/http://www.bloggingstocks.com/2009/12/21/celgene-remains-in-an-uptrend/http://www.bloggingstocks.com/2009/12/21/celgene-remains-in-an-uptrend/#commentsFiled under:

Celgene Corp.'s (CELG) stock has encountered resistance at $58, but I'm nevertheless reiterating my buy rating for the company's shares, first recommended on June 19, 2009, at a price of $46.94. Here's why:

Look for Celgene's FY2010 revenue to increase 20-23%, on top of a likely a 15-20% rise in FY2009, boosted by cancer treatments Revlimid's and Vidaza's sales. Further, pipeline candidates to treat psoriasis and small cell lung cancer are approaching late-stage study.

Continue reading Celgene Remains in an Uptrend

Celgene Remains in an Uptrend originally appeared on BloggingStocks on Mon, 21 Dec 2009 17:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>cancercelgCelgene Corp.psoriasisrevlimidvidazaMon, 21 Dec 2009 17:00:00 EST<![CDATA[Celgene (CELG): Cancer progress boosts biotech]]>http://www.bloggingstocks.com/2009/08/19/celgene-celg-cancer-progress-boosts-biotech/http://www.bloggingstocks.com/2009/08/19/celgene-celg-cancer-progress-boosts-biotech/http://www.bloggingstocks.com/2009/08/19/celgene-celg-cancer-progress-boosts-biotech/#commentsFiled under: , ,

"Some sectors tend to do better than others in tough times; biotechnology often surprises investors in good times and bad," suggests Brandon Clay.

In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review.

"This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals.

"However, despite the risks, there are times when we believe that individual biotech stocks make sense -- such as our latest recommendation for Celgene.

Continue reading Celgene (CELG): Cancer progress boosts biotech

Celgene (CELG): Cancer progress boosts biotech originally appeared on BloggingStocks on Wed, 19 Aug 2009 14:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech stocksbiotechnology stocksBiotechStocksbrandon claycancer drug stockscancer stockscancer treatment stocksCancerStocksCancerTreatmentStockscelgcelgeneinvest with an edgeInvestWithAnEdgerevlimidsteven halpernStevenHalpernthestockadvisors.comWed, 19 Aug 2009 14:00:00 EST<![CDATA[Time to scoop up some shares of Celgene]]>http://www.bloggingstocks.com/2009/06/19/time-to-scoop-up-some-shares-of-celgene/http://www.bloggingstocks.com/2009/06/19/time-to-scoop-up-some-shares-of-celgene/http://www.bloggingstocks.com/2009/06/19/time-to-scoop-up-some-shares-of-celgene/#commentsFiled under:

Pharmaceutical company Celgene Corp., beaten down by Wall Street for the better part of 10 months, is now a Buy in these circles. Here's why:

Analysts now expect FY2009 revenue to increase 15-18%, boosted by Revlimid and Vidaza sales. Further, pipeline candidates in psoriasis and small cell lung cancer are nearing late-stage study. The First Call FY2009/FY2010 EPS estimates for CELG are $2.04 to $2.65.

Continue reading Time to scoop up some shares of Celgene

Time to scoop up some shares of Celgene originally appeared on BloggingStocks on Fri, 19 Jun 2009 17:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>CELGCelgenerevlimidvidazaFri, 19 Jun 2009 17:00:00 EST<![CDATA[Best Stocks for 2008: Cancer drugs and controversy at Celgene (CELG)]]>http://www.bloggingstocks.com/2007/12/22/best-stocks-2008-cancer-drugs-and-controversy-at-celgene-celg/http://www.bloggingstocks.com/2007/12/22/best-stocks-2008-cancer-drugs-and-controversy-at-celgene-celg/http://www.bloggingstocks.com/2007/12/22/best-stocks-2008-cancer-drugs-and-controversy-at-celgene-celg/#commentsFiled under: , ,

For 25 years, Steven Halpern, editor of TheStockAdvisors.com, has surveyed the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is one of 100+ ideas in the Best Stocks for 2008 report.

"Our favorite more conservative stock for 2008 is Celgene (NASDAQ: CELG)," says biotech expert John McCamant, editor of The Medical Technology Stock Letter.

"The company is focused on the development of new and improved treatments for various cancers and other severe, immune, inflammatory conditions, and is well on its way to becoming a major global biopharmaceutical entity.

"Over the years, we have watched management consistently deliver on its promises to shareholders and create additional value. The most notable cancer drugs at CELG are Thalidomide and Revlimid (a second-generation version of Thalidomide).

"These are oral therapies that have become the cornerstone in the treatment of multiple myeloma (MM), and which are in clinical development for many other blood-borne cancers, including non-Hodgkin's lymphoma (NHL) and CLL.

Continue reading Best Stocks for 2008: Cancer drugs and controversy at Celgene (CELG)

Best Stocks for 2008: Cancer drugs and controversy at Celgene (CELG) originally appeared on BloggingStocks on Sat, 22 Dec 2007 10:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>best stocks 2008bioinvestbiotech stocksbiotechnology stockscelgcelgenefeaturedjohn mccamantJohnMccamantmedical technology stock letterRevlimidsteven halpernThalidomidethestockadvisors.comtop stocks 2008Sat, 22 Dec 2007 10:30:00 EST